Novel Coronavirus Characteristic Cerebrovasculopathic Effects
International Clinical Neuroscience Journal,
Vol. 7 No. 4 (2020),
28 Mehr 2020
,
Page 162-163
Abstract
Keywords:
- Coronavirus
How to Cite
1.
Zandpazandi S, Shahmohammadi MR. Novel Coronavirus Characteristic Cerebrovasculopathic Effects. Int Clin Neurosci J [Internet]. 2020 Sep. 28 [cited 2026 Jul. 25];7(4):162-3. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/32417
References
1. Padovani A. Special Report COVID-19: Neurologists Adapt in Northern Italy. (2020). Available online at: https://www.eanpages.org/2020/04/01/specialreport-covid-19-neurologists-adapt-in-northern-italy/ (accessed April 9, 2020)
2. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. (2020) e201127. doi: 10.1001/jamaneurol.202 0.1127. [Epub ahead of print].//// Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683–690.
3. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. (2020) 11:995–8. doi: 10.1021/acschemneuro.0c 00122
4. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. (2020). Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. doi: 10.1016/j.bbi.2020. 03.031. [Epub ahead of print].
5. Yaghi S, Ishida K, Torres J, et al. SARS2-CoV-2 and stroke in a New York Healthcare System. Stroke 2020. DOI: 10.1161/STROKEAHA.120.030335.
6. Wang A, Mandigo GK, Yim PD, Meyers PM and Lavine SD. Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. J Neurointerv Surg 2020; 12(7): 648–653.
7. Aggarwal G, Lippi G and Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature. Int J Stroke 2020; 15: 385–389.
8. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme2 (ACE2) asaSARS-CoV-2receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med.2020; 46(4):586-590.
9. Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. AmJPhysiolRegulIntegrCompPhysiol.2011; 300(4):R804-R817.
10. Urbanek C, Palm F, Grau AJ. Influenza and stroke risk: a key target not to be missed? Infect Disord Drug Targets.2010; 10(2):122-131.
11. Toschke AM, Heuschmann PU, Wood O, Wolfe CD. Temporal relationship between influenza infections and subsequent first-ever stroke incidence. Age Ageing. 2009; 38(1):100-103.
12. MehtaP, McAuley DF,Brown M,Sanchez E,Tattersall RS, MansonJJ. COVID19: consider cytokine storm syndromes and immunosuppression. Lancet North Am Ed.2020; 395(10229):1033-1034.
13. Connors JM, Levy JH. Thrombo inflammation and the hypercoagulability of COVID-19. J Thromb Haemost. Published online: April 17, 2020. (doi:10.1111/jth.14849).
14. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19.NEnglJMed.2020;382(17):e38.
15. . Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet North Am Ed. 2020; 395(10234):14171418.
16. Sweid A, Hammoud B, Bekelis, Missios S, Tjoumakaris S I, Gooch MR 1, Herial NA , Zarzour H, Romo V, DePrince M, Rosenwasser RH and Jabbour P. International Journal of Stroke 0(0) 1–10 ! 2020 World Stroke Organization Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/1747493020937189 journals.sagepub.com/home/wso
17. Sweid A, Hammoud B, Weinberg JH, Oneissi M, Raz E, Shapiro M, DePrince M, Tjoumakaris S, Gooch MR, Herial NA, Zarzour H, Romo V, Rosenwasser RH, Jabbour P. Letter: Thrombotic Neurovascular Disease in COVID-19 Patients, volume0, number0, 2020 www.neurosurgery-online.com
18. Ntaios G, Michel P, Jabbour P, et al. Characteristics and Outcomes in Patients with COVID-19 and Acute Ischemic Stroke the Global COVID-19 Stroke Registry. Stroke. 2020; 51:00–00.DOI:10.1161/STROKEAHA.120.031208
2. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. (2020) e201127. doi: 10.1001/jamaneurol.202 0.1127. [Epub ahead of print].//// Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683–690.
3. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. (2020) 11:995–8. doi: 10.1021/acschemneuro.0c 00122
4. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. (2020). Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. doi: 10.1016/j.bbi.2020. 03.031. [Epub ahead of print].
5. Yaghi S, Ishida K, Torres J, et al. SARS2-CoV-2 and stroke in a New York Healthcare System. Stroke 2020. DOI: 10.1161/STROKEAHA.120.030335.
6. Wang A, Mandigo GK, Yim PD, Meyers PM and Lavine SD. Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. J Neurointerv Surg 2020; 12(7): 648–653.
7. Aggarwal G, Lippi G and Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature. Int J Stroke 2020; 15: 385–389.
8. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme2 (ACE2) asaSARS-CoV-2receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med.2020; 46(4):586-590.
9. Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. AmJPhysiolRegulIntegrCompPhysiol.2011; 300(4):R804-R817.
10. Urbanek C, Palm F, Grau AJ. Influenza and stroke risk: a key target not to be missed? Infect Disord Drug Targets.2010; 10(2):122-131.
11. Toschke AM, Heuschmann PU, Wood O, Wolfe CD. Temporal relationship between influenza infections and subsequent first-ever stroke incidence. Age Ageing. 2009; 38(1):100-103.
12. MehtaP, McAuley DF,Brown M,Sanchez E,Tattersall RS, MansonJJ. COVID19: consider cytokine storm syndromes and immunosuppression. Lancet North Am Ed.2020; 395(10229):1033-1034.
13. Connors JM, Levy JH. Thrombo inflammation and the hypercoagulability of COVID-19. J Thromb Haemost. Published online: April 17, 2020. (doi:10.1111/jth.14849).
14. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19.NEnglJMed.2020;382(17):e38.
15. . Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet North Am Ed. 2020; 395(10234):14171418.
16. Sweid A, Hammoud B, Bekelis, Missios S, Tjoumakaris S I, Gooch MR 1, Herial NA , Zarzour H, Romo V, DePrince M, Rosenwasser RH and Jabbour P. International Journal of Stroke 0(0) 1–10 ! 2020 World Stroke Organization Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/1747493020937189 journals.sagepub.com/home/wso
17. Sweid A, Hammoud B, Weinberg JH, Oneissi M, Raz E, Shapiro M, DePrince M, Tjoumakaris S, Gooch MR, Herial NA, Zarzour H, Romo V, Rosenwasser RH, Jabbour P. Letter: Thrombotic Neurovascular Disease in COVID-19 Patients, volume0, number0, 2020 www.neurosurgery-online.com
18. Ntaios G, Michel P, Jabbour P, et al. Characteristics and Outcomes in Patients with COVID-19 and Acute Ischemic Stroke the Global COVID-19 Stroke Registry. Stroke. 2020; 51:00–00.DOI:10.1161/STROKEAHA.120.031208
- Abstract Viewed: 404 times
- PDF Downloaded: 353 times